Moore Capital Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Moore Capital Management’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-166,666	Closed	-$3.17K	–	649
2023 Q1	$3.17K	Hold	166,666	–	–	﹤0.01%	467
2022 Q4	$24.8K	Hold	166,666	–	–	﹤0.01%	420
2022 Q3	$28K	Hold	166,666	–	–	﹤0.01%	504
2022 Q2	$22K	Hold	166,666	–	–	﹤0.01%	559
2022 Q1	$132K	Hold	166,666	–	–	﹤0.01%	529
2021 Q4	$100K	Hold	166,666	–	–	﹤0.01%	616
2021 Q3	$158K	Hold	166,666	–	–	﹤0.01%	620
2021 Q2	$233K	Buy	+166,666	New	+$145K	﹤0.01%	631

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Moore Capital Management's PEARW Position: Q2 2023 in Review

Moore Capital Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 166,666 shares — an estimated $3.17K sold.

Moore Capital Management first reported a position in PEARW in Q2 2021 and held it in 8 quarters. The position peaked at $233K in Q2 2021. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

Moore Capital Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Moore Capital Management sold 166,666 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $3.17K.
Moore Capital Management first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 8 quarters.
Moore Capital Management's Pear Therapeutics, Inc. Warrant position peaked at $233K in Q2 2021.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on Moore Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.